Analysis of genetic aberrations on chromosomal region 8q21-24 identifies E2F5 as an oncogene with copy number gain in prostate cancer

Zhao, Jin; Wu, Xin-yang; Ling, Xiao-hui; Lin, Zhuo-yuan; Fu, Xin; Deng, Ye-han; He, Hui-chan; Zhong, Weide
March 2013
Medical Oncology;Mar2013, Vol. 30 Issue 1, p1
Academic Journal
The copy number gain of genes in chromosomal region 8q21-24 has been demonstrated to be associated with genesis and progression of prostate cancer (PCa). The aim of this study was to identify novel and effective molecular markers in this chromosomal region for PCa. The differentially expressed genes in PCa specimens were screened by gene microarray analysis, which was validated by RT-QPCR analysis. Then, the DNA qPCR analysis was carried out to detect the copy number changes of these differentially expressed genes. Moreover, the clinical significance of candidate markers (MYC and E2F5) in PCa were further determined. E2F5 and MYC were identified as candidate markers in PCa tissues and PCa cell lines. The DNA qPCR revealed the significant copy number gains of E2F5 and MYC in PCa tissues but not in PCa cell lines. In addition, Western blot analysis and immunohistochemical staining both found the significant higher expression of E2F5 and MYC proteins in PCa tissues than those in adjacent benign specimens (all P < 0.01). Moreover, the overexpression of E2F5 protein was significantly associated with a high Gleason score ( P < 0.01), an advanced clinical stage ( P = 0.01), a positive metastasis ( P < 0.01) and PSA Failure ( P < 0.01). The overexpression of MYC was more frequently found in PCa tissues with positive metastasis ( P = 0.02) and PSA failure ( P = 0.02). Interestingly, there was a close correlation in the expression level of MYC in PCa tissues with that of E2F5 ( r = 0.5, P ≤ 0.001). Our data offers the convincing evidence that the copy number gains of E2F5 and MYC may play an important role in genesis and progression of PCa. Especially, E2F5 may be a novel potential candidate marker for malignant PCa.


Related Articles

  • A Novel Protein Is Lower Expressed in Renal Cell Carcinoma. Ruili Guan; Yongde Xu; Hongen Lei; Zhezhu Gao; Zhongcheng Xin; Yinglu Guo // International Journal of Molecular Sciences;May2014, Vol. 15 Issue 5, following p7398 

    Engrailed-2 (EN2) has been identified as a candidate oncogene in breast cancer and prostate cancer. It is usually recognized as a mainly nuclear staining in the cells. However, recent studies showed a cytoplasmic staining occurred in prostate cancer, bladder cancer and clear cell renal cell...

  • Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer. Dawson, Dawn M.; Lawrence, Earl G.; MacLennan, Gregory T.; Amini, Saeid B.; Kung, Hsing-Jien; Robinson, Dan; Resnick, Martin I.; Kursh, Elroy D.; Pretlow, Theresa P.; Pretlow, Thomas G.; Dawson, D M; Lawrence, E G; MacLennan, G T; Amini, S B; Kung, H J; Robinson, D; Resnick, M I; Kursh, E D; Pretlow, T P; Pretlow, T G // JNCI: Journal of the National Cancer Institute;04/01/98, Vol. 90 Issue 7, p519 

    Background: The RET proto-oncogene encodes a protein that belongs to the tyrosine kinase growth factor receptor family. Germline point mutations in RET are found in individuals with multiple endocrine neoplasia (MEN) syndromes, and gene rearrangements have been reported in papillary...

  • Traversing the genomic landscape of prostate cancer from diagnosis to death. Hieronymus, Haley; Sawyers, Charles L // Nature Genetics;Jun2012, Vol. 44 Issue 6, p613 

    The clinical spectrum of prostate cancer ranges from curable, local disease to widely metastatic, lethal cancer. Two new prostate cancer genome studies provide the first glimpse at both ends of this spectrum.

  • Specific Genomic Regions Are Differentially Affected by Copy Number Alterations across Distinct Cancer Types, in Aggregated Cytogenetic Data. Kumar, Nitin; Cai, Haoyang; Von Mering, Christian; Baudis, Michael; Tan, Patrick // PLoS ONE;Aug2012, Vol. 7 Issue 8, Special section p1 

    Background: Regional genomic copy number alterations (CNA) are observed in the vast majority of cancers. Besides specifically targeting well-known, canonical oncogenes, CNAs may also play more subtle roles in terms of modulating genetic potential and broad gene expression patterns of...

  • Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer. Freytag, S O; Barton, K N; Zhang, Y // Gene Therapy;Dec2013, Vol. 20 Issue 12, p1131 

    Oncolytic adenovirus-mediated suicide gene therapy has been shown to improve local tumor control in preclinical tumor models and in the clinic. Although local tumor control is important, for most human cancers, new therapies must also target metastatic disease if they are to have an impact on...

  • Orphan receptor GPR110, an oncogene overexpressed in lung and prostate cancer. Lum, Amy M.; Wang, Bruce B.; Beck-Engeser, Gabriele B.; Li, Lauri; Channa, Namitha; Wabl, Matthias // BMC Cancer;2010, Vol. 10, Special section p1 

    Background: GPR110 is an orphan G protein-coupled receptor--a receptor without a known ligand, a known signaling pathway, or a known function. Despite the lack of information, one can assume that orphan receptors have important biological roles. In a retroviral insertion mutagenesis screen in...

  • Selective Expression of Myosin IC Isoform A in Mouse and Human Cell Lines and Mouse Prostate Cancer Tissues. Ihnatovych, Ivanna; Sielski, Neil L.; Hofmann, Wilma A. // PLoS ONE;Sep2014, Vol. 9 Issue 9, p1 

    Myosin IC is a single headed member of the myosin superfamily. We recently identified a novel isoform and showed that the MYOIC gene in mammalian cells encodes three isoforms (isoforms A, B, and C). Furthermore, we demonstrated that myosin IC isoform A but not isoform B exhibits a tissue...

  • EXPRESSION OF KI-67 AS A PROLIFERATION MARKER IN PROSTATE CANCER. Sulik, Marian; Maruszak, Klaudia; Puchalska, Joanna; Misiukiewicz-Poć, Magdalena // Polish Annals of Medicine / Rocznik Medyczny;2011, Vol. 18 Issue 1, p12 

    Introduction. Prostate carcinoma (PCa) is the most common male cancer found in industrialized societies and represents a serious public health problem. Delineation of gene expression patterns in early PCa that correlate with an aggressive phenotype is a priority and may allow for radical...

  • High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer. Melling, Nathaniel; Harutyunyan, Levon; Hube-Magg, Claudia; Kluth, Martina; Simon, Ronald; Lebok, Patrick; Minner, Sarah; Tsourlakis, Maria Christina; Koop, Christina; Graefen, Markus; Adam, Meike; Haese, Alexander; Wittmer, Corinna; Steurer, Stefan; Izbicki, Jakob; Sauter, Guido; Wilczak, Waldemar; Schlomm, Thorsten; Krech, Till // PLoS ONE;7/31/2015, Vol. 10 Issue 7, p1 

    Hook microtubule-tethering protein 3 (HOOK3) is an adaptor protein for microtubule-dependent intracellular vesicle and protein trafficking. In order to assess the role of HOOK3 in prostate cancer we analyzed HOOK3 expression by immunohistochemistry on a TMA containing more than 12,400 prostate...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics